glp 1 drugs and fatty liver GLP-1 Your Liver: What to Monitor While on Semaglutide or Tirzepatide Therapeutic Mechanisms and Clinical Effects
Description
Moore said the company expects to gain Food and Drug Administration approval of the Wegovy pill by the end of 2025 and make the medication available to consumers by early 2026
Clinical guidelines support the use of these medications for patients with obesity or type 2 diabetes when lifestyle modifications alone are insufficient
Wegovy generally produces roughly twice as much average weight loss as Saxenda based on trial data
In fact, the opposite may be true
